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The synthesis of fatty acids and cholesterol, the building blocks of
membranes, is regulated by three membrane-bound transcription
factors: sterol regulatory element-binding proteins (SREBP)-1a, -1c,
and -2. Their function in liver has been characterized in transgenic
mice that overexpress each SREBP isoform and in mice that lack all
three nuclear SREBPs as a result of gene knockout of SREBP
cleavage-activating protein (SCAP), a protein required for nuclear
localization of SREBPs. Here, we use oligonucleotide arrays hybrid-
ized with RNA from livers of three lines of mice (transgenic for
SREBP-1a, transgenic for SREBP-2, and knockout for SCAP) to
identify genes that are likely to be direct targets of SREBPs in liver.
A total of 1,003 genes showed statistically significant increased
expression in livers of transgenic SREBP-1a mice, 505 increased in
livers of transgenic SREBP-2 mice, and 343 showed decreased
expression in Scap livers. A subset of 33 genes met the stringent
combinatorial criteria of induction in both SREBP transgenics and
decreased expression in SCAP-deficient mice. Of these 33 genes, 13
were previously identified as direct targets of SREBP action. Of the
remaining 20 genes, 13 encode enzymes or carrier proteins in-
volved in cholesterol metabolism, 3 participate in fatty acid me-
tabolism, and 4 have no known connection to lipid metabolism.
Through application of stringent combinatorial criteria, the trans-
genicknockout approach allows identification of genes whose
activities are likely to be controlled directly by one family of
transcription factors, in this case the SREBPs.
The two major building blocks for animal cell membranes arecholesterol and fatty acids. Their synthesis begins with a
common precursor, acetyl-CoA, which originates from the ca-
tabolism of carbohydrates, proteins, and lipids. Acetyl-CoA is
converted to cholesterol in a pathway involving at least 23
enzymes. Acetyl-CoA is also polymerized to form fatty acids in
a pathway involving up to 12 enzymatic steps. Many of the
mRNAs encoding enzymes in these two pathways are regulated
coordinately by the sterol regulatory element-binding protein
(SREBP) family of membrane-bound transcription factors (1).
The three SREBP isoforms in mammals are designated SREBP-
1a, SREBP-1c, and SREBP-2 (2). They belong to the basic helix–
loop–helix leucine zipper (bHLH-Zip) family of transcription
factors. Unlike other bHLH-Zip proteins, SREBPs are intrinsic
membrane proteins of the endoplasmic reticulum (ER). All
SREBP precursors consist of an NH2-terminal 500 aa that
contains the bHLH-Zip region, two hydrophobic transmembrane-
spanning segments interrupted by a short30-aa segment, and an
590-aa COOH-terminal domain that has a regulatory function.
The NH2-terminal segment of SREBP, designated the nuclear form
(nSREBP), must be released from the membrane so that it can
enter the nucleus and activate transcription of target genes.
The release of active nSREBPs requires two sequential cleav-
ages (2). This process is initiated when the COOH-terminal
domain of the membrane-bound SREBP binds to SREBP
cleavage-activating protein (SCAP). SCAP serves both as a
sensor of sterols and as an escorter of SREBPs. When the ER
membrane becomes depleted in cholesterol, SCAP escorts
SREBP from the ER to the Golgi, where it is cleaved sequen-
tially by two proteases to liberate the nSREBP. In the nucleus,
nSREBPs bind to 10-bp repeats known as sterol response
elements located in the promoters of target genes (2).
When the cholesterol content of the ER membrane rises, a
conformational change in SCAP facilitates its binding to one of
two related proteins designated Insig-1 and Insig-2 (3, 4). This
interaction results in the retention of the SCAPSREBP com-
plex in the ER, thus preventing its incorporation into ER
transport vesicles. The net result is that SREBPs no longer are
processed proteolytically in the Golgi, their bHLH-Zip domains
cannot be released from the ER membrane, and the transcrip-
tion of target genes is reduced.
When expressed at superphysiologic levels, the nuclear forms
of all three SREBPs activate genes encoding multiple enzymes
in the cholesterol and fatty acid biosynthetic pathways as well as
the low-density lipoprotein (LDL) receptor (1). The relative
activities of the three isoforms differ. SREBP-1a is a potent
activator of all SREBP-responsive genes, owing to its long
transactivation domain encoded by its first exon. SREBP-1c, an
alternatively spliced version of SREBP-1a, differs from
SREBP-1a by only the first exon. In SREBP-1c, this exon
encodes a shorter transactivation domain that is less potent than
SREBP-1a (1). Although they differ in potency, SREBP-1a and
-1c both activate genes involved in the synthesis of fatty acids and
their incorporation into triglycerides and phospholipids.
SREBP-2, encoded by a different gene, preferentially activates
genes for cholesterol synthesis and the LDL receptor (5).
The function of SREBPs in vivo has been characterized through
studies in transgenic and knockout mice that overexpress or lack
single components of the SREBP pathway (1). The overexpression
of nSREBP-1a produced the most dramatic phenotype. These
transgenic mice developed a massive fatty liver engorged with both
triglycerides and cholesteryl esters (6). Genes controlling fatty acid
synthesis were more dramatically activated than those for choles-
terol synthesis. The preferential activation of fatty acid synthesis
(26-fold increase) relative to cholesterol synthesis (5-fold increase)
explained the greater accumulation of hepatic triglycerides. Over-
expression of the weaker nSREBP-1c in liver of transgenic mice
produced a triglyceride-enriched fatty liver with no increase in
cholesterol (1). Overexpression of nSREBP-2 in liver increased the
mRNAs encoding all cholesterol biosynthetic enzymes, the most
dramatic of which was a 75-fold increase in 3-hydroxy-3-
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methylglutaryl coenzyme A reductase mRNA (5). There was a
lesser effect on mRNAs necessary for fatty acid synthesis. The in
vivo rate of cholesterol synthesis was increased 28-fold in transgenic
nSREBP-2 livers, whereas fatty acid synthesis was increased only
4-fold.
Germ-line deletion of genes required for SREBP processing
(Scap or one of the proteases) results in early embryonic death
(1). To study the metabolic consequence of total nSREBP
deficiency in liver, we produced conditional knockouts of Scap
in adult mouse liver by using the Cre-lox recombination system
(7). The disruption of Scap dramatically reduced nSREBP-1 and
nSREBP-2 in liver and the coordinate expression of their target
genes in the cholesterol and fatty acid biosynthetic pathways. As
a result, the rates of cholesterol and fatty acid synthesis fell by
70–80% in livers of Scap knockout mice.
Although many direct targets of SREBP action have been
identified through studies of SREBP binding to enhancer re-
gions, the list is likely incomplete. Direct SREBP targets cannot
be identified by DNA sequence alone because sequences rec-
ognized by SREBPs show great variability among genes, and no
universal consensus sequence can be formulated (8).
In the current paper, we attempt to identify direct SREBP targets
through the use of microarray analysis. This goal was accomplished
by using Affymetrix oligonucleotide arrays hybridized with RNA
from livers of three types of mice: transgenic mice that overexpress
nSREBP-1a (TgSREBP-1a), transgenic mice that overexpress
nSREBP-2 (TgSREBP-2), and knockout SCAP mice (Scap)
that manifest reduced expression of all SREBPs. As a strict criteria
for SREBP target genes, we selected genes that were up-regulated
in both transgenic models and down-regulated in Scap mice.
This filter identified 33 genes, 13 of which are known direct targets
of SREBP action. The remaining 20 had not been identified
previously as direct SREBP target genes.
Methods
Methods for confirmatory cDNA microarray studies and real-time
PCR may be found in Supporting Methods, which is published as
supporting information on the PNAS web site, www.pnas.org.
Animals. The transgenic mice that overexpress transcriptionally
active nuclear forms of human SREBP-1a (TgSREBP-1a) or
SREBP-2 (TgSREBP-2) and mice that lack SCAP (Scap) in
liver have been described (5–7). All mice were housed in colony
cages in rooms maintained on a 12-h light12-h dark cycle and
fed Teklad MouseRat Diet no. 7002 from Harlan Teklad
Premier Laboratory Diets (Madison, WI). The transgenic mouse
studies included five 12- to 16-wk-old male TgSREBP-1a and
TgSREBP-2 mice and 5 male littermate wild-type controls that
were fed a high proteinlow carbohydrate diet for 2 weeks before
killing (6). This diet was used to elicit high-level expression of the
nSREBPs, whose promoters were driven by the phosphoenol-
pyruvate carboxykinase (PEPCK) enhancer, the expression of
which is increased by low carbohydrate diet (6). Studies using
liver-specific Scap mice included five 10- to 12-wk-old male
Scap;MX1-Cre and corresponding wild-type mice that re-
ceived four i.p. injections of polyinosinic-polycytidylic acid to
induce the Cre recombinase as described (7). These mice were
fed the Teklad chow and killed 14 days after the last injection.
RNA Isolation, Affymetrix Oligonucleotide Array Hybridization, and
Data Analysis. Total RNA was prepared from each liver by using
RNA STAT-60 (Tel-Test, Friendswood, TX). Equal aliquots of
total RNA from each of five mouse livers in each group were
pooled (total, 20 g) and used for biotin labeling as described in
the Affymetrix technical bulletin. Hybridization, washing, scan-
ning, and analysis of the Affymetrix GeneChip Murine Genome
MU74A, -B, and -C version 2 arrays (Affymetrix, Santa Clara,
CA) were carried out as described (9). Duplicate hybridizations
were performed with each RNA sample. Data obtained from the
microarray hybridizations was processed with MICROARRAY
SUITE 5.0 (Affymetrix) software.
Results
The expression of 36,700 transcripts represented on the Af-
fymetrix Mouse Genome MU74A, -B, and -C version 2 microar-
rays was quantified in pooled liver samples from transgenic mice
that overexpress nSREBP-1a or nSREBP-2 or that have a
deficiency of all SREBP isoforms as a result of deleting Scap in
liver. Duplicate hybridizations were performed for each sample.
Overall, 8,000 transcripts (22%) were expressed in livers of
wild-type mice (identified as ‘‘present’’ by Affymetrix software).
The TgSREBP-1a mouse livers expressed 9,229 transcripts,
TgSREBP-2 livers 8,341 transcripts, and Scap livers 7,719
transcripts (Table 5, which is published as supporting informa-
tion on the PNAS web site).
Using the Mann–Whitney ranking feature of the Affymetrix
software as criteria for statistical significance, we identified 1,003
transcripts as increased in livers of TgSREBP-1a mice, 505
increased in the TgSREBP-2 mice, and 343 decreased in Scap
mice. The majority of these changes are not caused by direct
actions of SREBPs but are secondary to the long-term changes
in metabolism that occur when nSREBP levels are manipulated.
To identify genes that are likely to be direct targets of
nSREBPs, we filtered genes according to various criteria out-
lined in Tables 1–4. The most stringent criteria are shown in
Table 1, which lists genes whose mRNAs were increased 2.5-
fold in livers of both TgSREBP-1a and TgSREBP-2 mice and
decreased by 40% in Scap mice. These highly stringent
criteria identified most, but not all, of the genes previously
identified as direct SREBP targets on the basis of short-term
transcription reporter assays in cultured cells andor DNA
binding assays. Thirty-three genes met these stringent criteria
(Table 1). Nineteen genes encode proteins that participate in
cholesterol biosynthesis and 1 in cholesterol uptake (low-density
lipoprotein receptor). Ten of these 19 cholesterol-related genes
had been characterized previously as direct SREBP targets
(denoted by symbol ‡ in Table 1) (1, 8).
In addition to the 19 cholesterol biosynthetic genes, 3 genes
encode proteins involved in other aspects of sterol metabolism:
Insig-1, Narc-1, and StarD4 (Table 1). Insig-1 blocks SREBP
activation by inhibiting movement of the SCAPSREBP complex
from the ER to the Golgi in the presence of sterols (3). Its
up-regulation by SREBPs provides a feedback mechanism to
reduce SREBP cleavage when adequate sterol levels are present in
cells. A potential SREBP-binding site exists in the promoter of
Insig-1, but analysis of promoter function has not been performed.
Narc-1 is a serine protease that belongs to the proteinase K
subfamily of subtilases (10). Mutations in its human orthologue
cause a rare autosomal dominant form of hypercholesterolemia,
suggesting that Narc-1 is involved in lipid metabolism (11). Its
regulation by SREBPs has not been reported previously. StarD4
was recently identified in microarray analysis of mouse liver as
a gene that is negatively regulated by cholesterol feeding,
consistent with it being an SREBP target (12). Although the
function of StarD4 is not known, it belongs to a family of proteins
that contain a START (steroidogenic acute regulatory protein–
related lipid transfer) domain. The founding member of this
family, StAR, delivers cholesterol to the mitochondria in steroi-
dogenic cells (12), but it is not expressed in liver. A second family
member, StarD3MNL64, binds cholesterol in vitro (13), but is
not regulated by SREBPs. Like its relatives, StarD4 may be
involved in sterol transport, and a potential SREBP-binding site
is present in the StarD4 promoter (12).
Among the 33 genes that met the strict criteria of Table 1, 6
are involved in fatty acid, triglyceride, and phospholipid synthe-
sis. Three were previously characterized as direct SREBP targets
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(denoted by ‡ in Table 1) (1). One additional gene, long-chain
fatty acyl elongase, is regulated by SREBPs, although no formal
promoter studies have been performed (1). Cytochrome b5 is a
membrane-bound protein that donates electrons to a variety of
acceptors that are intermediates in fatty acid desaturation as well
as cholesterol biosynthesis (14). The induction of cytochrome b5
is likely required to maintain the high rates of cholesterol and
fatty acid biosynthesis present in livers of SREBP transgenic
mice. In addition to the above 6 genes, 2 genes listed under
cholesterol synthesis (acetyl-CoA synthetase and ATP citrate
lyase) also participate in fatty acid biosynthesis.
Three genes listed in Table 1 are labeled ‘‘miscellaneous,’’ and
one encodes a novel protein of unknown function. The three
miscellaneous genes may have indirect roles in lipid metabolism.
Aldolase C is a glycolytic enzyme that catalyzes the cleavage of
fructose-1,6-bisphosphate, which produces glyceraldehyde-3-
phosphate and dihydroacetone phosphate, the fourth step in
the glycolytic pathway. Up-regulation of aldolase C by SREBPs may
increase the supply of acetyl-CoA for fatty acid and cholesterol
biosynthesis. Mac30 is structurally related to the family of insulin-
like growth factor binding proteins, but its function is unknown. The
short-chain aldehyde reductase (SCALD) was recently identified as
a gene activated by SREBPs by using suppressive subtractive
hybridization of tissues from TgSREBP-1a mice (15). SCALD
catalyzes the reduction of potentially toxic short-chain fatty alde-
hydes, such as nonanal and 4-hydroxynonenal, converting them to
less toxic alcohols. Fatty aldehydes can be formed when unsatur-
ated fatty acids undergo oxidation; thus, it is hypothesized that
regulation of SCALD by SREBPs is a protective cellular response
to increased production of unsaturated fatty acids that occurs when
SREBPs are activated.
Table 2 lists genes whose expression was increased in livers of
TgSREBP-1a mice, reduced in Scap mice, and unchanged in
TgSREBP-2 mice. Nine genes involved in fatty acid synthesis and
Table 1. Genes whose transcripts in mouse liver increase in TgSREBP-1a,
increase in TgSREBP-2, and decrease in Scap/
Gene
Relative expression Data base ID
Transgenic
SREBP-1a
Transgenic
SREBP-2
SCAP
knockout GenBank Affymetrix
For each group, total RNA from the pooled livers of five mice was prepared for Affymetrix
oligonucleotide hybridization as described in Methods. The relative mRNA expression of each
gene in livers from the indicated transgenic or knockout mice compared to the appropriate
wild-type controls is shown. Results from duplicate hybridizations are listed in each column, with
red indicating a relative increase and green a relative decrease in mRNA expression. Genes are
grouped according to function and are listed in alphabetical order under each heading. TG,
triglycerides; PL, phospholipids.
*Gene expression changes that have been verified by one or more methods, i.e., northern gel
analysis, real-time PCR, or cDNA microarrays (Table 7, which is published as supporting infor-
mation on the PNAS web site).
‡Genes previously characterized as directly regulated by SREBPs (1).
¶The enzymes produced by these genes also participate in fatty acid synthesis (see Fig. 2).
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metabolism were identified, 3 of which [acetyl-CoA carboxy-
lase-2, glycerol-3-phosphate acyltransferase, and stearoyl-CoA
desaturase (SCD)] were previously identified as SREBP target
genes (1, 16, 17). Of the remaining 4 genes, 2 (acyl-CoA
synthetase-4 and fatty acid CoA ligase, long-chain 5) add the
CoA moiety to long-chain fatty acids, resulting in their activa-
tion, a step required for their incorporation into triglycerides,
phospholipids, and cholesteryl esters. The last 2 identified genes
involved in fatty acid synthesis and metabolism (L-specific
multifunctional -oxidation protein and a putative enoyl-CoA
acyl-CoA hydratasedehydrogenase) are both likely to be per-
oxisomal enzymes involved in the oxidation of very long-chain
fatty acids. Whether these are direct targets of SREBP-1a, or
whether they are activated as a secondary response to increased
fatty acid levels, is unknown.
In the miscellaneous and unclassified categories of Table 2, only
spot 14 was previously described as a direct transcriptional target of
SREBPs (18). Spot 14 mRNA levels are regulated in a manner
similar to all genes involved in lipogenesis; its function is not known
(19). Three of the miscellaneous genes in Table 2 (cysteine sulfinic
acid decarboxylase; glutathione S-transferase, mu-6; and glutathi-
one S-transferase, theta-3) may protect cells from oxidative prod-
ucts. Cysteine sulfinic acid decarboxylase converts cysteine sulfinate
to taurine, which may protect cells from oxidative injury through
formation of taurine chloramines that are produced by myeloper-
oxidase (20). The general function of glutathione S-transferases is
to detoxify compounds by addition of glutathione sulfhydryl groups
to electrophilic molecules. The physiologic substrates of the mu-6
and theta-3 forms of glutathione S-transferase are not known, but
they may be induced to detoxify oxidized lipids that may accumulate
in the fatty livers of the TgSREBP-1a mice. Six additional members
of the glutathione S-transferase family (theta-1, theta-2, mu-2,
mu-5, and glutathione peroxidases-3 and -4) were increased in
TgSREBP-1a mouse livers, but not decreased in livers of Scap
mice (see Table 5).
Table 3 lists 10 genes whose pattern of expression was
increased in livers of TgSREBP-2 mice, decreased in Scap
mice, and unchanged in TgSREBP-1a mice. Two of the 10 genes
are in the cholesterol biosynthetic pathway, one of which,
mevalonate kinase, was strikingly increased (40-fold) in Tg-
SREBP-2 livers and markedly decreased (92%) in livers of
Scap mice (Table 3). The 8 miscellaneous and unclassified
genes have no obvious connection to lipid metabolism.
Table 4 lists 25 genes whose pattern of expression was
increased in livers of TgSREBP-1a and TgSREBP-2 mice and
unchanged in livers of Scap mice. This pattern of regulation
suggests that these 25 genes are capable of responding to
SREBPs, either directly or indirectly, but their basal expression
does not require nSREBPs. Two ATP-binding cassette proteins,
ABCG5 and ABCG8, are directly involved in sterol metabolism.
These proteins form heterodimers that transport sterols across
the plasma membrane in liver and intestine (21). Mutations in
either ABCG5 or ABCG8 result in -sitosterolemia, an autoso-
mal recessive human disorder characterized by increased intes-
tinal absorption and decreased biliary excretion of dietary sterols
and hypercholesterolemia (21). The only characterized tran-
Table 2. Genes whose transcripts in mouse liver increase in
TgSREBP-1a, decrease in Scap/, and are unchanged
in TgSREBP-2
Gene
Relative expression Data base ID
Transgenic
SREBP-1a
SCAP
knockout GenBank Affymetrix
See legend to Table 1. Oligonucleotides did not distinguish between SCD-1
and SCD-3 (see Fig. 2).
Table 3. Genes whose transcripts in mouse liver increase in
TgSREBP-2, decrease in Scap/, and are unchanged
in TgSREBP-1a
Gene
Relative expression Data base ID
Transgenic
SREBP-2
SCAP
knockout GenBank Affymetrix
See legend to Table 1.
Table 4. Genes whose transcripts in mouse liver increase in
TgSREBP-1a, increase in TgSREBP-2, and are unchanged
in Scap/
Gene
Relative expression Data base ID
Transgenic
SREBP-1a
Trangenic
SREBP-2 GenBank Affymetrix
See legend to Table 1.
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scriptional regulators of ABCG5 and ABCG8 are the nuclear
receptors LXR- and LXR- (22). Activation of cholesterol
biosynthesis by SREBPs produces endogenous oxysterol ligands
that activate LXR (23), which in turn transcriptionally activates
expression of ABCG5 and ABCG8.
Three additional genes involved in fatty acid and phospholipid
metabolism (fatty acid CoA ligase, long chain-3; phospholipid
transfer protein; and SCD-2) were markedly increased in
TgSREBP-1a and TgSREBP-2 livers. Fatty acid CoA ligase is
involved in the activation of fatty acids. Phospholipid transfer
protein, like ABCG5 and ABCG8, is regulated by LXRs (24) and
may be increased as a result of activation of this nuclear receptor.
Previously, SCD-2 was identified as an SREBP target gene (16).
SCD-2 is not normally expressed in livers of wild-type mice, but
is expressed in TgSREBP-1a and -2 livers, thus explaining why
it was not detected as decreased in livers of Scap mice (19).
Fifteen genes are listed in the miscellaneous category in Table
4. Aquaporin-8 is a member of a family of membrane proteins
that function as water-selective channels. Aquaporin-8 has been
localized intercellularly to the canalicular membrane, which
suggests that it may be involved in water transport into bile (25).
Biliary cholesterol secretion is markedly increased in SREBP
transgenic mice (J.D.H., unpublished observations), and this
may be coupled with enhanced water excretion.
Four of the 15 genes in the miscellaneous category of Table 4
(aldehyde dehydrogenase family 1; biliverdin reductase B; gluta-
thione S-transferase, mu-5; and nuclear factor, erythoid-derived-2)
have roles in protecting cells from oxidative injury. Cytosolic
aldehyde dehydrogenase participates in the oxidation of various
aldehydes, including all-trans-retinal and 4-hydroxynonenal, a ma-
jor aldehyde product of lipid peroxidation (26). Biliverdin, a
product of heme oxygenase activity, is metabolized by biliverdin
reductase to produce bilirubin, which is a potent antioxidant (27).
In formulating the criteria in Tables 1–4, we included only those
genes whose mRNAs rose by2.5-fold or declined to60% of the
basal value. The Affymetrix software identifies mRNAs that change
in a statistically significant manner without regard to arbitrary
cutoffs. Table 6 (which is published as supporting information on
the PNAS web site) compares the number of genes that meet our
criteria and the Affymetrix statistical criteria. In each case, the
Affymetrix criteria identified additional genes whose expression
changed in a statistical sense, but 2.5-fold.
Discussion
In the current experiments, we devise a method of combinatorial
analysis of microarrays to define a set of genes whose transcrip-
tion in liver increases in response to elevated nSREBPs and
whose basal expression depends on SREBPs, as indicated by a
fall in mRNA levels in Scap liver. Genes that satisfy these
stringent criteria are likely to be directly responsive to SREBPs
by virtue of SREBP binding sites in their enhancer regions. This
conclusion is supported by the finding that 19 of 23 genes in the
cholesterol biosynthetic pathway met these stringent criteria
(Table 1). The same is true for 5 of 10 genes in the pathway for
synthesis of fatty acids.
In revealing genes that are direct SREBP targets, the combined
microarray analysis may suggest a function for the encoded gene
products. One example is 17--hydroxysteroid dehydrogenase-7,
which meets the stringent criteria for direct SREBP regulation and
shows highest expression in TgSREBP-2 mice, suggesting that it
plays a role in cholesterol synthesis. This enzyme reduces the
17-keto group of estrone, converting it to estradiol (28). However,
it is possible that this enzyme also reduces the 3-keto group of
cholesterol precursors, a necessary step in cholesterol synthesis and
one for which no enzyme has heretofore been identified.
Among the 33 genes that met the strict criteria for SREBP
gene targets, there was a relative difference between those
involved in cholesterol and fatty acid metabolism. In general, the
cholesterol-related genes tended to be more strongly activated by
overexpression of nSREBP-2 and the fatty acid-related genes
were more strongly affected by nSREBP-1a (see Tables 1–3).
Fig. 1 lists the known enzymes in the cholesterol biosynthetic
pathway and indicates the average fold activation of each gene in
Fig. 1. SREBP-2 mediated activation of the entire pathway for cholesterol
synthesis in mammalian cells. Key biosynthetic intermediates are highlighted in
yellow. Red italics denotes the fold increase in mRNA levels for each enzyme in
TgSREBP-2 liver. Each value is the average of the two microarray hybridizations
listed in Tables 1 and 3. *, Desmosterol reductase was not represented on the
microarray. The fold-increase value is from real-time PCR. †, 17-Hydroxysteroid
dehydrogenase-7 has not been confirmed as a cholesterol biosynthetic enzyme.
Fig. 2. SREBP-1a mediated activation of pathways for monounsaturated and
polyunsaturated fatty acid synthesis in mammalian cells. Fatty acid products
are highlighted in yellow. Red italics denotes the fold increase in mRNA levels
for each enzyme in TgSREBP-1a liver. Each value is the average of the two
microarray hybridizations listed in Tables 1 and 2 except as indicated. *, Results
are from real-time PCR.
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TgSREBP-2 mice. Twenty-two of the 23 genes were analyzed on the
microarray. The remaining gene (desmosterol reductase) was not
present on the chip, but was analyzed in the same RNA samples by
real-time PCR. All of these genes were activated in TgSREBP-2
mice, and the fold increase in mRNA ranged from 2.6-fold to
40-fold (median of 9.9-fold). Nineteen of the 23 genes met stringent
criteria of increased expression in both transgenics and decreased
expression in Scap liver. Two of the four exceptions were
acetyl-CoA acetyltransferase-2 and mevalonate kinase, which were
elevated by 10- and 40-fold, respectively, in TgSREBP-2 mice and
decreased by 65% and 90%, respectively, in Scapmice, but were
not elevated in TgSREBP-1a mice (Table 2). A third exception,
3-hydroxysteroid-8,7-isomerase, just missed the stringent cri-
teria for inclusion (see Table 6), but was recently identified as a
direct SREBP target (29). The fourth exception, desmosterol
reductase, was not represented on the microarray, but its regulation
was confirmed by real-time PCR.
Fig. 2 shows the fold increase in TgSREBP-1a mice of genes
that participate in the synthesis of fatty acids. The most highly
induced genes were those responsible for synthesis of monoun-
saturated fatty acids (acetyl-CoA carboxylase-1, fatty acid syn-
thase, long-chain fatty acyl elongase, and SCD-1, -2, and -3). As
indicated by the marked fold-increase values, SCD-2 and SCD-3
are essentially only expressed in liver under conditions of
SREBP activation. The enzymes required for elongation of very
long-chain polyunsaturated fatty acids (6-desaturase, Elovl5,
5-desaturase, and Elovl2) were induced, but to a lesser extent
than those involved in monounsaturated fatty acid synthesis.
The filter afforded by the combined use of transgenic and
knockout mice helped to eliminate genes that are activated indi-
rectly by the products of SREBP action, rather than by SREBP
directly. For example, we were able to exclude genes that are
regulated by the nuclear receptors LXR and LXR. LXRs form
heterodimers with retinoid X receptors (RXR) and are activated by
a variety of sterols, including oxysterol intermediates in the syn-
thesis of cholesterol (23, 30). The increase in cholesterol biosyn-
thesis that results from SREBP overexpression produces endoge-
nous ligands that activate LXR. Using the combined approach, we
identified phospholipid transfer protein, lipoprotein lipase,
ABCG5, and ABCG8 as genes activated in transgenic livers, but not
decreased in livers of Scap mice (Table 4). These genes are
known to be activated by LXR. Two additional LXR-regulated
genes, SREBP-1c and fatty acid synthase, also contain SREBP-
binding sites in their promoters (30–32) and were correctly iden-
tified as direct SREBP target genes (Table 1).
The current studies also illustrate the importance of correlat-
ing tissue culture promoter-reporter assays with results in rele-
vant organs in vivo. In cultured cells, overexpressed SREBPs
bind to the promoters of and activate the transcription of genes
encoding apoAII, (33) and SR-BI (34). However, in Tg-
SREBP-1a and TgSREBP-2 livers, no induction of the mRNA
for these two genes was observed nor did their expression
decrease in Scap mice. Similarly, in vitro studies showed that
SREBP-2 inhibits the transcription of Cyp8bl (35), a finding that
was not reproduced in livers of TgSREBP-2 and Scap mice.
In addition to genes that met stringent criteria for SREBP
regulation, we identified 600 transcripts that were significantly
increased in livers of TgSREBP-1a mice without change in the
other gene-manipulated mice (Tables 5 and 6). In these cases,
induced gene expression was most likely a secondary effect, owing
to the enhanced lipid synthesis and accumulation in TgSREBP-1a
mice. Although these are not direct effects, the characterization of
the secondary effects may also provide important insight into the
regulation of other metabolic pathways or disease processes.
One such example comes from further analysis of genes
activated in TgSREBP-1a livers. A well-documented association
exists between fat accumulation in liver and the development of
nonalcoholic steatohepatitis (NASH), which can lead to cirrhosis
and liver failure (36). NASH can result from hepatocellular
injury, owing to oxidant stress. Lipid peroxidation leads to the
formation of several membrane-derived products, including
unsaturated aldehydes that potentiate oxidant stress. The in-
creased expression of certain aldehyde reductases (SCALD and
alcohol dehydrogenase family-1, subfamily A7) may be a re-
sponse to the increased formation of these products. At least 10
additional genes involved in the detoxification of oxidized lipids
(8 glutathione S-transferase family members; cysteine sulfinic
acid decarboxylase; and M-LP, Mpv17-like protein) were also
induced in TgSREBP-1a mouse livers. It is likely that these
changes in gene expression occur in response to the excessive
fatty acids that accumulate in livers of TgSREBP-1a mice. The
full characterization of these effects and identification of the
mediators of these gene changes may give important clues into
the sequence of events that result in liver damage in fatty livers.
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